Atlas Trials

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

Clinical trial NCT06109233 · UNKNOWN

Trial details

NCT number
NCT06109233
Sponsor
FengYan Jin
Status
UNKNOWN
Study type
OBSERVATIONAL
Multiple MyelomaMinimal Residual Disease
Start date
2022-01-10
Primary completion
2025-01-10
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.